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Abstract
Trichloroethylene (TCE) is a widely used organic solvent. Although TCE is classified as 
carcinogenic to humans, substantial gaps remain in our understanding of inter-individual 
variability in TCE metabolism and toxicity, especially in the liver. We tested a hypothesis that 
amounts of oxidative metabolites of TCE in mouse liver are associated with liver-specific toxicity. 
Oral dosing with TCE was conducted in sub-acute (600 mg/kg/d; 5 days; 7 inbred mouse strains) 
and sub-chronic (100 or 400 mg/kg/d; 1, 2, or 4 weeks; 2 inbred mouse strains) designs. We 
evaluated the quantitative relationship between strain-, dose-, and time-dependent formation of 
TCE metabolites from cytochrome P450-mediated oxidation [trichloroacetic acid (TCA), 
dichloroacetic acid (DCA), and trichloroethanol] and glutathione conjugation [S-(1,2-
dichlorovinyl)-L-cysteine and S-(1,2-dichlorovinyl)glutathione] in serum and liver, and various 
liver toxicity phenotypes. In sub-acute study, inter-strain variability in TCE metabolite amounts 
was observed in serum and liver. No induction of Cyp2e1 protein levels in liver was detected. 
Serum and liver levels of TCA and DCA were correlated with increased transcription of 
peroxisome proliferator-marker genes Cyp4a10 and Acox1, but not with degree of induction in 
hepatocellular proliferation. In sub-chronic study, serum and liver levels of oxidative metabolites 
gradually decreased over time despite continuous dosing. Liver protein levels of Cyp2e1, Adh and 
Aldh2 were unaffected by treatment with TCE. While the magnitude of induction of peroxisome 
proliferator-marker genes also declined, hepatocellular proliferation increased. This study offers a 
unique opportunity to provide a scientific data-driven rationale for some of the major assumptions 
in human health assessment of TCE.
Introduction
Trichloroethylene (TCE) is a chlorinated organic solvent widely used as a feedstock material 
in chemical manufacturing, as well as in various industrial applications including dry 
cleaning and vapor degreasing. Since the beginning of its wide-spread production dating 
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back to the 1920s (NICNAS 2000), it has been recognized as an occupational and 
environmental health concern due to high human exposure and its potential to be a health 
hazard (NRC 2006). The number of workers in occupations with likely TCE exposure has 
declined in the developed countries in the past 20 years (von Grote et al. 2003). Still, TCE is 
one of the major contaminants found in the Superfund hazardous waste sites across the 
United States (U.S. EPA 2011) and is ranked 16th on the Substance Priority List by the US 
Agency for Toxic Substances and Disease Registry (ATSDR 2011).
TCE poses a potential human health hazard for non-cancer toxicity to the central nervous 
system, kidney, liver, immune system, male reproductive system, and the developing fetus 
(Chiu et al. 2013). In addition, TCE is classified as carcinogenic to humans by IARC (Guha 
et al. 2012) and the U.S. EPA (U.S. EPA 2011) based on the evidence in humans of a causal 
relationship between kidney cancer and exposure to TCE. Positive, although less consistent, 
associations with TCE were reported studies of liver cancer and non-Hodgkin lymphoma 
(Scott and Jinot 2011).
Liver toxicity and carcinogenicity remain largely unresolved with regard to the human 
health hazard of TCE (Rusyn et al. 2014). There is clear evidence that TCE is a liver 
carcinogen in rodents (National Toxicology Program 1990; Anna et al. 1994); however, the 
relationship between occupational TCE exposure and risk of liver cancer in humans is still 
inconclusive, given that epidemiologic studies have observed both positive (Hansen et al. 
2013) and negative associations (Vlaanderen et al. 2013; Radican et al. 2008). A recent 
meta-analysis reported a meta-relative risk of 1.3 (95% CI 1.1–1.6) for the overall TCE 
exposure and liver cancer based on nine human cohorts (Scott and Jinot 2011).
There are also uncertainties regarding the potential mode of action for TCE tumorigenesis in 
liver (Rusyn et al. 2014). TCE is metabolized through both cytochrome P450-dependent 
oxidation and glutathione conjugation to form a number of toxic species (Lash et al. 2014). 
Metabolites of the oxidative pathway, trichloroacetic (TCA) and dichloroacetic (DCA) 
acids, are widely considered to be primary mediators of the toxicity and carcinogenicity of 
TCE in the liver via peroxisome proliferator-activated receptor (PPARα) activation. The 
latter is one of the most studied mechanisms of action for TCE-induced liver cancer in 
rodents (Klaunig et al. 2003; Keshava and Caldwell 2006). Studies in vitro have shown that 
human PPARα is activated by TCA and DCA, but relatively inactive to TCE itself (Maloney 
and Waxman 1999; Zhou and Waxman 1998). In addition, human hepatocytes transfected 
with mouse PPARα displayed increased expression of PPARα, and increased peroxisome 
proliferator response element-reporter activity when treated with TCA and DCA (Walgren et 
al. 2000).
Even though it is widely assumed that tissue-specific formation of TCE metabolites is one of 
the critical determinants for the plethora of its adverse health effects, most studies of TCE 
toxicokinetics were performed in blood. Few studies evaluated TCE metabolism in tissues, 
however one study in rats did not find a dose-response relationship in formation of TCE 
metabolites in liver and kidney (Lash et al. 2006). Thus, we tested a hypothesis that 
formation of oxidative metabolites of TCE in mouse liver is associated with liver-specific 
toxicity by evaluating the quantitative relationship between strain-, dose-, and time-
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dependent formation of TCA and DCA in serum and liver, and various liver toxicity 
phenotypes in a panel of mouse inbred strains.
Materials and Methods
Animals and treatments
Male mice (aged 6–7 weeks) were purchased from the Jackson Laboratory (Bar Harbor, 
ME) and housed in polycarbonate cages on Sani-Chips (P.J. Murphy Forest Products Corp., 
Montville, NJ) irradiated hardwood bedding. Animals were fed an NTP-2000 (Zeigler 
Brothers, Inc., Gardners, PA) wafer diet and water ad libitum on a 12 h light-dark cycle. All 
studies were approved by the UNC Institutional Animal Care and Use Committee.
Two study designs were utilized in this work. First, we performed a sub-acute study where 
vehicle (10 mL/kg, 5% Alkamuls EL-620 in saline) or TCE (600 mg/kg/d, in vehicle) was 
administered by gavage to mice from 7 inbred strains (129S1/SvImJ, A/J, BTBR T+tf/J, 
C57BL/6J, CAST/EiJ, NOD/ShiLtJ, and NZW/LacJ) for 5 consecutive days. These strains 
were selected to maximize inter-strain differences in metabolism of TCE based on the 
previous study of TCE metabolism in a panel of inbred strains (Bradford et al. 2011) and the 
results of the statistical modeling of the effect of time and strain on TCE metabolite 
concentrations which supports the sample size used in this study (Chiu et al. 2014). Second, 
based on the data from the sub-acute study, we selected two inbred strains (C57BL/6J and 
NZW/LacJ) that represented widely varying degrees of formation of oxidative metabolites 
of TCE for a subsequent sub-chronic study. Specifically, animals of each strain were 
randomly assigned to one of the three groups (5% Alkamuls EL-620 in saline vehicle, 100, 
or 400 mg/kg/d of TCE) and were dosed by oral gavage daily for 5 days, 2 weeks, or 4 
weeks (the latter two were dosed for 5 days/week).
In all studies, mice were given drinking water containing 0.2 g/L of 5-bromo-2′-
deoxyuridine (BrdU) for 72 h prior to sacrifice. Blood, tissues (liver, kidney, etc.) and a 
section of a duodenum were collected 2 hrs after the last treatment. The timing of sacrifice 
was selected based on the toxicokinetic studies of TCE in the mouse (Bradford et al. 2011; 
Kim et al. 2009b) showing that concentrations of both oxidative and glutathione conjugation 
metabolites of TCE peak around 2 hrs after dosing. Blood was drawn from vena cava and 
centrifuged to prepare serum using Z-gel tubes (Sarstedt, Germany) according to the 
manufacturer’s instructions. Body and organ weights were recorded. Liver and duodenum 
sections were fixed in neutral buffered formalin for 24 hrs, and the remainder of the liver 
tissue was frozen in liquid nitrogen. All serum and tissue samples were stored at −80°C until 
analyzed.
Quantification of TCE metabolites
Concentrations of TCA, DCA, S-(1,2-dichlorovinyl)-L-cysteine (DCVC), and S-(1,2-
dichlorovinyl) glutathione (DCVG) in serum and liver were determined using HPLC-ESI-
MS/MS as detailed elsewhere (Kim et al. 2009a) with slight modifications. Quantification of 
trichloroethanol (TCOH) in liver was performed using the method of (Song and Ho 2003). 
The configuration of the instruments was identical to that in the above mentioned references, 
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but the extraction methods were optimized for each tissue (liver or serum) and metabolite as 
follows.
TCA and DCA—Serum (50 μL) was mixed with 100 μL of the internal standards 
(difluoroacetic acid (DFA) and trifluoroacetic acid (TFA), 50 nmol/mL each). Serum 
proteins were then removed by filter-centrifugation (Microcon YM-10; Millipore, Billerica, 
MA) at 14,000×g for 1 hr. Liver samples (100 mg) were homogenized in 500 μL of 0.01 M 
PBS (pH 7.4) with 20 μL of internal standards (DFA and TFA, 20 nmol/mL each) using 
Tissuelyser (Qiagen, Valencia, CA) for 1 min. The homogenates were filter-centrifuged 
(Amicon Ultra Centrifugal Filters 10K; Millipore) at 14,000×g for 1 hr. After the filtrate was 
acidified with 100 μL of 3% (v/v) sulfuric acid, 2 mL of diethyl ether was added and 
solutions were vortexed vigorously for 1 min. The upper ether layer was transferred to 
another vial, reduced in volume to less than 300 μL under continuous stream of N2, then 
transferred to a glass vial insert containing 5 μl of double-distilled water and dried 
completely. The residue was reconstituted in 20 μL of HPLC mobile phase consisting of 
70% acetonitrile, 30% 1 mM ammonium citrate in double-distilled water. The lower limits 
of quantification (LLOQ) were: 0.04 nmol/mL in serum and 0.1 nmol/g in liver for DCA, 5 
nmol/mL in serum and 8 nmol/g in liver for TCA.
DCVG and DCVC—Serum (50 μL) was mixed with 100 μL of the internal standard 
solution ([13C2,15N]DCVG and [13C3,15N]DCVC, 5 nmol/mL each). Serum proteins were 
then removed by filter-centrifugation (Microcon YM-10; Millipore) at 14,000×g for 1 hr. 
Liver tissue (100 mg) was homogenized in 500 μL of 0.01 M PBS (pH 7.4) with 20 μL of 
internal standards ([13C2,15N]DCVG and [13C3,15N]DCVC, 25 nmol/mL each) using 
Tissuelyser (Qiagen) for 1 min. The homogenates were filter-centrifuged (Amicon Ultra 
Centrifugal Filters 10K; Millipore) at 14,000×g for 1 hr. From each prepared sample, DCVG 
and DCVC were extracted using a solid phase extraction cartridge (StrataTM X-AW, 30mg 
96-well plate; Phenomenex, Torrance, CA). The cartridges were conditioned with 300 μL of 
methanol, followed by equilibration with 300 μL of water. Samples were loaded, washed 
with 300 μL of water, and eluted with 250 μL of basic methanol (pH adjusted to 10.8 by 
29.1% NH4OH). The final eluent was collected in 300 μL glass vial inserts and dried in a 
SpeedVac Concentrator before reconstitution with 20 μL of 4:1 water/methanol containing 
0.1% acetic acid. The LLOQ were: 0.5 pmol/mL in serum and 2 pmol/g in liver for DCVG, 
1 pmol/mL in serum and 20 pmol/g in liver for DCVC.
TCOH—Liver tissue (30 mg) was homogenized in 500 μL of acetate buffer (pH 4.6) with 
1,000 units of β-glucuronidase (Sigma [G0751], St. Louis, MO) using Tissuelyser (Qiagen) 
for 1 min, followed by overnight incubation at 37°C. After centrifugation at 14,000×g for 5 
min, the supernatant was transferred to a new tube, then mixed with 20 μL internal standard 
(DCA, 10 mM in methanol) and 550 μL of water/0.1 M sulfuric acid/methanol (6:5:1). The 
mixture was heated at 70°C for 20 min. After cooling to room temperature, 2.5 mL hexane 
was added, the mixture vortexed for 10 min and centrifuged at 2,500×g for 2 min. The upper 
layer was concentrated under a stream of N2 to less than 20 μL and used for GC-MS analysis 
as detailed in (Song and Ho 2003). The LLOQ was 5 nmol/g in liver.
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Gene expression analysis by real-time PCR
Total RNA was isolated from liver samples using an RNeasy kit (Qiagen) according to the 
manufacturer’s instructions. RNA concentration and quality were determined using an 
ND-1000 spectrophotometer (Nanodrop Technologies, Wilmington, DE) and Agilent 2000 
Bioanalyser, respectively. Total RNA was reverse transcribed using random primers and the 
high capacity complementary DNA archive kit (Applied Biosystems, Foster City, CA) 
according to the manufacturer’s protocol. The following gene expression assays (Applied 
Biosystems) were used for quantitative real-time PCR: PPARα (Mm00440939_m1); 
palmitoyl acyl-Coenzyme A oxidase 1 (Acox1, Mm01246831_m1); cytochrome P450, 
family 4, subfamily a, polypeptide 10 (Cyp4a10, Mm01188913_g1); and beta glucuronidase 
(Gusb, Mm00446953_m1). Reactions were performed in a 96-well plate, and all samples 
were plated in duplicate using a LightCycler® 480 instrument (Roche Applied Science, 
Indianapolis, IN). The cycle threshold (Ct) for each sample was determined from the linear 
region of the amplification plot. The ∆Ct values for all genes relative to the control gene 
Gusb were determined. The ∆∆Ct were calculated using treated group means relative to 
strain-matched control group means. Fold change data were calculated from the ∆∆Ct 
values.
Protein level measurements
Proteins were extracted from 20 mg of frozen liver samples using T-PER® Tissue Protein 
Extraction Reagent (Pierce Biotechnology, Rockford, IL) and Halt™ Protease Inhibitor 
Cocktail (Pierce Biotechnology) according to the manufacturer’s instructions. Protein 
concentration was measured using Pierce® BCA Protein Assay Kit (Pierce Biotechnology) 
and a DTX 880 Multimode Detector (Beckman Coulter, Brea, CA). Extracts containing 30 
μg of protein were resolved on 12% polyacrylamide sodium dodecyl sulfate-containing gels 
and transferred to polyvinylidene difluoride membranes. Membranes were blocked in 
Odyssey® Blocking Buffer (LI-COR, Lincoln, NE) and probed with 1:5000 diluted anti-
Cytochrome P450 2e1 antibody (Abcam, Cambridge, MA), anti-Aldh2 antibody (Abcam), 
or anti-Adh antibody (Abcam) overnight at 4°C. Blots were washed in 0.1% Tween20 in 
0.01 M PBS, incubated with 1:20,000 IRDye® 680LT donkey anti-rabbit IgG (LI-COR), 
and detected using an Odyssey Infrared Imaging System (LI-COR). Equal protein loading 
was confirmed by total protein staining with 0.1% (w/v) naphthol blue black in 7% (v/v) 
acetic acid in water for 10 min. The signal intensity was analyzed by Image Studio Software 
(LI-COR).
Statistical analysis
The significance of inter-strain effect on metabolism was assessed by ANOVA modeling. 
Given the small sample size, the exact permutation test was used to determine significant 
differences between control and TCE-treated groups (α=0.05). The Spearman (rank) 
correlation analysis across all variables was conducted to account for the difference in scale 
of the variables. In correlation analyses, false discover rate correction (Storey and Tibshirani 
2003) was applied to all p-values to correct for multiple comparisons. The resultant 
significant (<0.1) q-values are reported in the Supplemental Tables. All statistical analyses 
were performed using SAS software ver. 9.3 (SAS Institute, Cary, NC).
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Individual animal-level data for all quantitative endpoints is available publicly at the Mouse 
Phenome Database (http://phenome.jax.org/; accession ID: Rusyn6).
Results
Sub-acute (5 days) studies of strain-dependent effects of TCE in mouse liver
We evaluated serum and liver levels of TCE metabolites from P450-mediated oxidation 
(TCA, DCA, TCOH) and glutathione conjugation (DCVC and DCVG) in seven mouse 
inbred strains (Figure 1). Mice were treated for 5 days by oral gavage of 600 mg/kg of TCE 
in aqueous vehicle. Across all strains, serum levels (Figure 1, left panel) of TCA were on 
average 1,000-fold greater than those for DCA, and the amounts of DCA were about 100-
fold higher than those of either DCVC or DCVG. Higher levels of TCA (about 2-fold) and 
DCA (about 10-fold) were found in liver (Figure 1, right panel) than in serum, but the 
relative ratio of TCA to DCA was similar. The levels of TCOH, also a major TCE 
metabolite in liver, were comparable to those of TCA. Levels of DCVG were much higher 
in liver than in serum (about 100-fold) and only about 10-fold lower than those of DCA. We 
observed a substantial difference between the concentrations of DCVG and DCVC in liver. 
While the amounts of DCVG and DCVC in serum were comparable (<2-fold difference), 
the concentration of DCVG in liver was at least 50 to 100-fold higher than that of DCVC, 
which was below the LLOQ in most samples. We found a significant strain effect (p<0.05) 
in both serum and liver for every metabolite examined (TCA, DCA, TCOH, DCVG, and 
DCVC).
We examined the relationships between TCE metabolites in either serum or liver 
(Supplemental Table 1). In serum, we found no significant correlations among 5 
metabolites. In liver, levels of TCA and DCA were significantly correlated (ρ=0.74, 
q=0.001). Although both TCA and TCOH are major oxidative metabolites, we found no 
correlation between their levels in liver. Inter-tissue (liver vs serum) correlation of TCE 
metabolites was also evaluated. We found significant correlation between liver and serum 
levels for TCA (ρ=0.62, q=0.020), serum TCA and liver DCA (ρ=0.78, q=0.001), and serum 
DCVC and liver DCVG (ρ=0.67, q=0.017).
To determine whether inter-strain differences in TCE metabolism may be due to strain-
dependent variability in expression of Cyp2e1, we measured the levels of liver Cyp2e1 
protein in vehicle- and TCE-treated animals (Figure 2). A significant strain effect (p<0.05) 
was found in baseline liver Cyp2e1 levels. However, treatment with TCE was without effect 
on liver Cyp2e1 across all strains. Interestingly, the background liver levels of Cyp2e1 were 
not correlated (ρ=0.74, p=0.055) with the amount of TCA in liver of TCE-treated animals.
Liver size (relative to body weight) and hepatocellular proliferation were examined in 
vehicle- and TCE-treated mice (Figures 3A–B). We observed significant effects of sub-acute 
treatment with TCE on liver enlargement in 129S1/SvlmJ, NOD/ShiLtJ and BTBR T+tf/J, 
and on hepatocyte proliferation in NOD/ShiLtJ, BTBR T+tf/J, and NZW/LacJ strains. 
Because peroxisome proliferation has been suggested as contributing to hepatomegaly in 
rodents (Marsman et al. 1988), we evaluated expression of Cyp4a10 and Acox1, marker 
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genes for this mechanistic event, in mouse liver. Expression of the transcription factor 
Ppara, was not affected by TCE (data not shown); however, expression of Cyp4a10 and 
Acox1 was markedly elevated in all strains, except for CAST/EiJ (Figures 3C–D), with 
TCE-induced effect being greater for Cyp4a10 than for Acox1.
Because inter-strain differences in both TCE metabolism and liver effects were observed in 
this study, we examined the associations among these endpoints in liver (Supplemental 
Table 2). Levels of TCA and DCA were strongly correlated with expression of Acox1 and 
Cyp4a10 (Figures 4A–B). However, neither the expression of Acox1 and Cyp4a10, nor the 
level of TCA, was correlated with hepatocellular proliferation (Figures 4C and 4D, 
respectively).
Sub-chronic (up to 4 weeks) studies of strain-dependent effects of TCE in mouse liver
Based on the differences in TCE metabolism observed in the sub-acute (5 days) TCE 
exposure studies, we selected C57BL/6J and NZW/LacJ strains to further test our hypothesis 
that inter-strain differences in amounts of oxidative metabolites of TCE in the liver are 
associated with liver-specific toxicity. In these studies, we examined the time-dependent (1, 
2 and 4 weeks) and dose-dependent (100 and 400 mg/kg/day, i.g.) effects of TCE.
As expected, the difference in TCE metabolism between two strains was also observed at 
lower doses and in longer-term studies (Figure 5). Serum and liver levels of TCA and DCA 
were higher in NZW/LacJ mice, and liver levels of DCVG were higher in C57BL/6J mice. 
Similar to the findings in the sub-acute study, levels of TCA and TCOH in liver were 100 to 
1,000-fold greater than those of DCA, and levels of DCA were 10 to 100-fold higher than 
those of DCVG. Levels of DCVC in serum and liver were below the LLOQ. Amounts of all 
measured TCE metabolites in liver and serum generally trended downward over time. 
Specifically, the levels of TCA in serum and liver decreased over time in both strains, while 
the levels of TCOH in liver decreased over time only in C57BL/6J strain. Likewise, the level 
of DCVG in liver was highest after 5 days of treatment.
Among TCE metabolites that were measured in this study, serum and liver levels of TCA 
and DCA were highly correlated (q<0.001) across all animals in the study (Supplemental 
Table 3). Liver levels of TCOH exhibited similar strong correlation with the levels of TCA 
and DCA in either serum or liver. No correlation was found among the levels of DCVG in 
liver and other TCE metabolites.
To examine whether strain-dependent changes in TCE-metabolizing enzymes could account 
for the observed decrease in metabolite formation over time, we examined the levels of 
Cyp2e1, Aldh2, and Adh proteins in liver, and found that expression of these enzymes was 
not affected by TCE treatment (Figure 6).
We also examined the effects of sub-chronic treatment with TCE on liver weight and the 
marker genes of hepatocellular proliferation and peroxisome proliferator expression. Even 
though the amount of oxidative metabolites of TCE trended downward over time, the 
increased liver to body weight ratio was still observed in mice treated for 2 week or 4 week 
in a strain-dependent manner. In the case of hepatocellular proliferation, most prominent 
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effects were observed at the 4 week time-point (Figures 7A–B). Histopathological 
evaluation of the liver sections revealed concordant increases in relative size of the 
hepatocytes, as well as hemosiderin deposits in the high-dose 4 week treatment groups of 
both strains (Supplemental Figure 1). A prominent effect of TCE on peroxisome 
proliferation in the liver was observed in the sub-chronic study. Although TCE did not affect 
expression of Ppara (data not shown), expression of Acox1 and Cyp4a10 was strongly 
induced in a dose-dependent manner in both strains of mice treated with TCE for 5 days 
(Figures 7C–D). Interestingly, the magnitude of upregulation of Acox1 and Cyp4a10 by 
TCE diminished over time. In the 2 and 4 week treatment groups, there was either no 
difference in gene expression between vehicle and TCE-treated animals, or differences were 
less prominent.
Similar to the result of the sub-acute study, the levels of TCA and DCA were significantly 
correlated with Acox1 and Cyp4a10 expression in liver regardless of TCE dose or treatment 
duration (Figures 8A–B). The Cyp4a10 expression was significantly correlated with liver-to-
body weight ratio (ρ=0.68, q<0.001, Figure 8C); however, hepatocellular proliferation did 
not correlate with other variables (Figure 8D, Supplemental Table 4).
Discussion
The challenge of addressing the variability in susceptibility to environmental exposures is 
frequently one of the most contentious issues in human health assessments. Because of the 
heterogeneity of the human population, it is generally expected that there will be a broad 
range of toxicokinetic and toxicodynamic responses to chemicals or drugs (Zeise et al. 
2013). Traditionally, the inter-individual differences in the toxicokinetics are accounted for 
by default assumptions and only in rare cases, are based on human toxicokinetic data. 
Seldom is there sufficient data to evaluate the extent of variability in toxicodynamics.
Because TCE metabolism to form chloroacetic acids and GSH-conjugates is widely 
accepted as the mechanism leading to toxicity in various organs (Lash et al. 2001), the 
interplay between toxicokinetics and toxicodynamics is a critically important consideration 
in the evaluation of human health hazard of TCE. Some understanding of the human 
population variability in toxicokinetics of TCE is available based on the limited data from 
clinical studies and Bayesian modeling (Chiu et al. 2009). The metabolism of TCE across 
species (e.g., rodents and humans) is qualitatively similar (Lash et al. 2014), and thus inter-
species and –individual variability in TCE toxicity is likely due to the variability in TCE 
metabolism (Chiu et al. 2013; Green 1990). TCE toxicity is also dose-dependent, which 
suggests the link between toxicokinetics and toxicodynamics (Chiu et al. 2013). It is yet to 
be experimentally demonstrated, however, that inter-individual variability in TCE 
metabolism, not exposure (i.e., dose), will result in quantitative differences in its toxicity. In 
this regard, an examination of the relationship between the variability of metabolism and the 
variability in toxicity may shed light on our understanding of human health hazard of TCE. 
Therefore, the purpose of this study was to use a population-based approach to test the 
hypothesis that TCE-induced toxicity in liver is associated with the liver-specific formation 
of oxidative TCE metabolites.
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In our previous work, we demonstrated that both oxidative metabolism and GSH 
conjugation of TCE vary considerably among inbred mouse strains (Bradford et al. 2011), 
and that such variability was associated with strain-specific differences in gene expression in 
mouse liver. While these results allowed for a quantitative evaluation of the relationship 
between metabolism and TCE-induced gene expression in the liver, the focus of the study 
was on toxicokinetic profiling over a 24 hour time period and the use of one high dose of 
TCE (2.1 g/kg, i.g.). To further explore the time- and dose-relationships between TCE 
metabolism and toxicity in the context of inter-strain variability, we conducted a series of 
studies that aimed to quantitate the levels of TCE metabolites in serum and liver. We also 
evaluated cell proliferation and peroxisome proliferation, two widely accepted liver toxicity 
phenotypes reflective of the major mechanistic events considered to play a role in liver 
carcinogenesis of TCE in rodents (Rusyn et al. 2014).
The first important and novel outcome of this study is quantitative data on a broad range of 
metabolites produced via oxidative metabolism and GSH conjugation of TCE in serum and 
liver in the context of inter-strain variability in TCE metabolism. While many published 
reports provide quantitative information on serum levels of TCA along with a few reports of 
DCA after treatment with TCE in rodents and humans, little information exists on the 
formation of these metabolites in the liver. Similar to our findings in the single-dose studies 
in mouse serum (Bradford et al. 2011; Kim et al. 2009b), there is up to 5 orders of 
magnitude difference in the relative flux of TCE through CYP450-dependent oxidation 
(primarily TCA) compared to GSH conjugation. The similarities in the levels of TCE 
metabolites formed through oxidation and GSH conjugation in this and our previous studies 
confirm that GSH conjugation of TCE is a minor pathway in mice, regardless of the dose or 
duration of treatment.
In the mouse liver, TCA was also the predominant metabolite formed (about 2 orders of 
magnitude greater than DCA); however, while the difference in relative flux of TCE through 
CYP450-dependent oxidation compared to GSH conjugation was still large, it was smaller 
than that in serum, about 3 orders of magnitude. In the rat liver, TCA and TCOH are also 
predominant TCE metabolites and there is about 100-fold difference between CYP450-
dependent oxidative metabolism and GSH-conjugation (Lash et al. 2006). TCE metabolism 
by CYP450-dependent pathway is known to occur at a faster rate in mice than in rats (Prout 
et al. 1985), and our data are in line with these observations.
Serum levels of TCA and DCA were not correlated with each other, which is consistent with 
our previous study (Kim et al. 2009b) that postulated that DCA formation is not occurring 
exclusively from TCA. However, we found that liver levels of TCA and DCA did correlate 
significantly, which supports a hypothesis that TCA is the major precursor for the formation 
of DCA in this organ (Ketcha et al. 1996). A detailed liver toxicokinetic study of oxidative 
metabolites of TCE may be necessary to further characterize the metabolic fate of TCA and 
DCA.
Our finding that the concentration of DCVG in liver was much higher than that in serum and 
higher than the concentration of DCVC in either serum or liver further demonstrates that 
TCE conjugation with GSH to form DCVG occurs predominantly in the liver (Lash et al. 
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2014). Given that DCVG is rapidly excreted into the bile (van Bladeren 2000), the relative 
flux of TCE through GSH conjugation in the liver may be even greater than that observed in 
our study. As it has been suggested that GSH conjugation may be much greater in humans 
than in rodents (Lash et al. 1999), careful estimation of the biliary excretion of GSH 
conjugates of TCE may be needed to completely understand the kinetics of this metabolic 
pathway.
Based on the levels of TCA and DCA observed in the sub-acute study (Figure 1), two strains 
were chosen, C57BL/6J and NZW/LacJ, which represent low or high levels of CYP450-
dependent oxidation of TCE, respectively. Time-course analysis of TCE metabolites in liver 
showed a decreasing trend of TCA and TCOH concentration, especially in the high dose 
(400 mg/kg/day) group. Previous studies of TCE metabolism showed that under conditions 
of acute exposure in mice, the induction of the monooxygenase system results in greater 
liver metabolism of TCE (Dekant et al. 1986) and no apparent saturation of metabolism is 
observed (Prout et al. 1985). However, saturation of TCE metabolism does occur in the rat 
liver at high doses (Prout et al. 1985; Dekant et al. 1986). A long-term study with TCE in 
rats and mice showed that daily dosing for 180 days did not induce the overall metabolism 
of TCE, but did double the urinary excretion of TCA (Green and Prout 1985).
The time-dependent change in kinetics may be explained by either auto-induction (Chaudhry 
et al. 2010) or depletion of co-substrates such as NADPH, NADH, and NAD+ (Lipscomb et 
al. 1996). Auto-induction may not explain our findings because Cyp2e1, Aldh2, and Adh, 
major enzymes involved in oxidative metabolism of TCE, were not affected by TCE dose or 
by the duration of exposure. In addition, it is possible that a decrease in TCE metabolism 
may be due to insufficient availability of co-substrates that are affected by not only by the 
extent of metabolism, but also by the redox status of the liver. Oxidative stress, as a 
secondary event that follows cytotoxicity and peroxisome proliferation in the liver, is one 
such mechanistic event. Several studies that examined TCA- and DCA-induced hepatic 
oxidative stress demonstrated small, albeit significant, increases in lipid peroxidation and 
oxidative DNA damage (Austin et al. 1996; Parrish et al. 1996). While we reason that the 
time-dependent decrease in TCE metabolism observed herein may plausibly result from the 
saturation of co-substrate supply or from oxidative stress, these mechanisms need further 
study.
The second important and novel outcome of our work is the investigation of the quantitative 
relationships among TCE metabolite levels and liver toxicity phenotypes. Because 
significant inter-strain variability was observed in TCE metabolism and liver toxicity, this 
study offers a unique opportunity to provide a scientific data-driven rationale for some of the 
major assumptions in human health assessment of TCE and other chlorinated solvents. 
Specifically, we examined major metabolizing enzymes responsible for oxidative 
biotransformation of TCE, as well as markers of cell proliferation and peroxisome 
proliferation in liver.
Inter- and intra-species differences in oxidative metabolism of TCE have been examined in 
relation to the expression levels of key xenobiotic metabolism enzymes, primarily CYP2E1 
(Lash et al. 2014). We observed a correlation between the amounts of TCA produced in liver 
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and a baseline Cyp2e1 protein level across strains. This finding may be attributable to the 
previously reported observation that not only is CYP2E1 involved in the first step of TCE 
oxidation, but CYP2E1 also catalyzes the transformation of TCOH to TCA (Stenner et al. 
1997). CYP2E1 is not the only CYP450 enzyme that may act on TCE. For example, liver 
Cyp2e1 content was found to be similar in rats and mice (Nakajima et al. 1993) even though 
major differences in TCE metabolism are known to exist between mice and rats. Human 
CYP1A1/2, CYP2A6, and CYP3A4 are also known to oxidize TCE, with CYP1A2 being 
the major alternative to CYP2E1 (Lash et al. 2014).
A recent study using a mouse model of the human population showed that TCE metabolism 
was strongly associated with induction of PPARα-mediated lipid and nucleic acid 
metabolism pathways in mouse liver regardless of the genetic background (Bradford et al. 
2011). In our study, we found that under conditions of sub-acute and sub-chronic treatment 
with TCE, significant up-regulation of Acox1 and Cyp4a10 expression occurred in 6 out of 7 
strains and the extent of gene expression was correlated with the liver levels of TCA and 
DCA. Strong correlation between TCA and DCA levels in liver makes it difficult to interpret 
their relative contributions to the induction of peroxisome proliferation response. However, 
DCA is widely regarded as a weaker ligand for PPARα activation compared to TCA 
(Corton 2008), and the amount of DCA detected in this study in the liver is orders of 
magnitude lower than that of TCA.
Similar to an observed time-dependent decrease in TCE metabolite formation, the 
expression levels in Acox1 and Cyp4a10 decreased over time in the sub-chronic study, 
which indicates a close association between peroxisome proliferation and the oxidative 
metabolism of TCE. Contrary to the decrease in the oxidative metabolism and peroxisome 
proliferation over time, liver enlargement and hepatocellular proliferation effects were most 
prominent in mice treated with TCE for 4 weeks. Neither TCA nor DCA in liver was 
correlated with hepatocellular proliferation in the sub-chronic study, which may suggest that 
multiple metabolites or pathways are likely to be involved in liver toxicity due to TCE 
(Rusyn et al. 2014).
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Figure 1. Inter-strain variability in TCE metabolism in the mouse in a sub-acute study
Serum (A-D) and liver (E-I) levels of metabolites were assessed 2 h following the last of 5 
daily doses (600 mg/kg) of TCE. Box and whisker plots are shown (+, mean; line, median; 
box, inter-quartile range; whiskers, min to max). When box is shown, 4 animals per group 
were available. Otherwise, there were 3 animals per group.
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Figure 2. Relationships between TCE metabolism in a sub-acute study and liver Cyp2e1 protein 
levels
(A) A representative Western blot of Cyp2e1 protein expression in liver of vehicle- and 
TCE-treated mice from CAST/EiJ and NZW/LacJ strains. (B) Inter-strain differences in 
basal and TCE-induced liver expression of Cyp2e1. Box and whiskers plots are shown (+, 
mean; line, median; box, inter-quartile range; whiskers, min to max). There were 3 animals 
per group. (C) Correlation between basal liver expression of Cyp2e1 and liver TCA amounts 
in TCE-treated mice of 7 strains. Each dot represents a mouse strain. Spearman rank (ρ) 
correlation is shown.
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Figure 3. Inter-strain differences in liver toxicity of TCE in a sub-acute study
Liver to body weight ratios (A), percent BrDU-positive hepatocyte nuclei (B), and liver 
expression of peroxisome proliferation marker genes Acox1 (C) and Cyp4a10 (D) were 
evaluated in mice treated with vehicle (white) or TCE (black; 600 mg/kg) for 5 days. Box 
and whiskers plots are shown (+, mean; line, median; box, inter-quartile range; whiskers, 
min to max). When box is shown, 4 animals per group were available. Otherwise, there were 
3 animals per group. Asterisk (*) denotes a significant difference (p<0.05) compared to 
vehicle-treated group within same strain.
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Figure 4. Correlation between TCE metabolites and liver toxicity phenotypes
TCE-induced increase in Cyp4a10 and Acox1 expression in the mouse liver was 
significantly correlated with liver levels of TCA (A) and DCA (B), and hepatocellular 
proliferation (C). Weak correlation was observed between TCA concentration in the liver 
and hepatocellular proliferation (D). Each symbol represents an individual animal in the 
study. Spearman rank (ρ) correlations and false discovery rate-corrected significance values 
(q<0.1) are shown.
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Figure 5. Time-course analysis of TCE metabolism in C57BL/6J and NZW/LacJ mice in a sub-
chronic study
Serum (A) and liver (B) levels of metabolites were assessed 2 h following the last dose after 
1, 2 or 4 wks (100 or 400 mg/kg/d) of TCE. Box and whiskers plots are shown (+, mean; 
line, median; box, inter-quartile range; whiskers, min to max). Light-gray, 100 mg/kg/d 
groups; dark gray, 400 mg/kg/d groups. When box is shown, 4 animals per group were 
available. Otherwise, there were 3 animals per group. Asterisks denote a significant (p<0.05) 
difference as compared to (*) the group dosed with 100 mg/kg/d (same strain and time 
point), (#) the 5 day treatment group (same strain and dose), or (&) the values in C57BL/6J 
strain (same dose and time point).
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Figure 6. The effect of a sub-chronic treatment with TCE on liver Cyp2e1 (A), Aldh2 (B) and 
Adh (C) protein levels in C57BL/6J and NZW/LacJ mice
Box and whiskers plots are shown (+, mean; line, median; box, inter-quartile range; 
whiskers, min to max). Thickness of the line corresponds to the vehicle, 100 and 400 
mg/kg/d groups. There were 3 animals per group.
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Figure 7. Differences in liver toxicity of TCE in C57BL/6J and NZW/LacJ mice in a sub-chronic 
study
Liver to body weight ratios (A), percent BrDU-positive hepatocyte nuclei (B), and liver 
expression of peroxisome proliferation marker genes Acox1 (C) and Cyp4a10 (D) were 
evaluated in mice treated with TCE (100 or 400 mg/kg) for 1, 2 or 4 wks. Box and whiskers 
plots are shown (+, mean; line, median; box, inter-quartile range; whiskers, min to max). 
White, vehicle-treated groups; light-gray, 100 mg/kg/d groups; dark gray, 400 mg/kg/d 
groups. When box is shown, 4 animals per group were available. Otherwise, there were 3 
animals per group. Asterisk (*) denotes a significant (p<0.05) difference as compared to 
vehicle-treated group (same strain and time point).
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Figure 8. Correlation between TCE metabolites and liver toxicity phenotypes in C57BL/6J and 
NZW/LacJ mice in a sub-chronic study
TCE-induced increase in Cyp4a10 and Acox1 expression in the mouse liver was 
significantly correlated with liver levels of TCA (A) and DCA (B), and liver to body weight 
ratio (C). (D) No correlation was observed between TCA concentration in the liver and 
hepatocellular proliferation. Each symbol represents an individual animal in the study. 
Spearman rank (ρ) correlations and false discovery rate-corrected significance values 
(q<0.1) are shown.
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